Kissin Dmitry M, Boulet Sheree L, Jamieson Denise J
Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, Georgia.
Obstet Gynecol. 2016 Aug;128(2):387-390. doi: 10.1097/AOG.0000000000001419.
The recently released National Public Health Action Plan for the Detection, Prevention, and Management of Infertility calls for better access to high-quality infertility services and improved safety of fertility treatments. Both assisted reproductive technology (ART) and non-ART fertility treatments have allowed millions of patients worldwide to overcome infertility-a disease of the reproductive system and important public health issue. However, there are substantial disparities in access to effective treatments in the United States, largely attributable to high out-of-pocket costs, especially for ART. Moreover, the outcomes of fertility treatments are often complicated by the large proportion of multiple births with substantial health risks for both neonates and mothers. Prevention of multiple births is difficult during non-ART fertility treatments but can be effective with single-embryo transfer during ART. Several U.S. states have enacted legislative mandates that require private insurers to cover some portion of the costs associated with fertility treatments and thus reduce the financial pressure to transfer multiple embryos during ART. Although studies have shown that insurance coverage reduces per-cycle multiple births to a certain degree, states with insurance mandates have more ART-related multiple births attributable to substantially larger number of ART-conceived neonates. Experience from other countries shows that access to ART can be improved without concomitant increases in multiple births by providing reimbursement for ART in combination with restrictions on the number of embryos transferred per cycle. Such approaches may or may not be successful in the United States with its unique and complex health care system.
最近发布的《国家不孕不育检测、预防及管理公共卫生行动计划》呼吁更好地提供高质量不孕不育服务,并提高生育治疗的安全性。辅助生殖技术(ART)和非辅助生殖技术的生育治疗都使全球数百万患者克服了不孕不育——这是一种生殖系统疾病,也是一个重要的公共卫生问题。然而,在美国,获得有效治疗的机会存在很大差异,这主要归因于高额的自付费用,尤其是辅助生殖技术的费用。此外,生育治疗的结果往往因多胎妊娠比例过高而变得复杂,这对新生儿和母亲都有很大的健康风险。在非辅助生殖技术的生育治疗中,预防多胎妊娠很困难,但在辅助生殖技术中进行单胚胎移植则可能有效。美国几个州已经颁布了立法规定,要求私人保险公司承担与生育治疗相关的部分费用,从而减轻辅助生殖技术过程中移植多个胚胎的经济压力。尽管研究表明,保险覆盖在一定程度上降低了每个周期的多胎妊娠率,但有保险规定的州因辅助生殖技术受孕的新生儿数量大幅增加,导致与辅助生殖技术相关的多胎妊娠更多。其他国家的经验表明,通过提供辅助生殖技术报销并限制每个周期移植的胚胎数量,可以在不增加多胎妊娠率的情况下改善辅助生殖技术的可及性。在美国独特而复杂的医疗体系下,这种方法可能成功,也可能不成功。